• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

5-硝基-1,10-菲啰啉对结核分枝杆菌的双重作用机制。

Dual Mechanism of Action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis.

机构信息

Vaccine and Infectious Disease Research Centre, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.

Eco-Friendly New Materials Research Centre, Korean Research Institute of Chemical Technology, Daejeon, South Korea.

出版信息

Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.00969-17. Print 2017 Nov.

DOI:10.1128/AAC.00969-17
PMID:28893784
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5655107/
Abstract

New chemotherapeutic agents with novel mechanisms of action are urgently required to combat the challenge imposed by the emergence of drug-resistant mycobacteria. In this study, a phenotypic whole-cell screen identified 5-nitro-1,10-phenanthroline (5NP) as a lead compound. 5NP-resistant isolates harbored mutations that were mapped to and were also resistant to the bicyclic nitroimidazole PA-824. Mechanistic studies confirmed that 5NP is activated in an F-dependent manner, resulting in the formation of 1,10-phenanthroline and 1,10-phenanthrolin-5-amine as major metabolites in bacteria. Interestingly, 5NP also killed naturally resistant intracellular bacteria by inducing autophagy in macrophages. Structure-activity relationship studies revealed the essentiality of the nitro group for activity, and an analog, 3-methyl-6-nitro-1,10-phenanthroline, that had improved activity and efficacy in mice compared with that of 5NP was designed. These findings demonstrate that, in addition to a direct mechanism of action against , 5NP also modulates the host machinery to kill intracellular pathogens.

摘要

需要新型作用机制的新型化疗药物来应对耐药分枝杆菌出现带来的挑战。在这项研究中,表型全细胞筛选发现 5-硝基-1,10-菲咯啉(5NP)是一种先导化合物。5NP 抗性分离株携带的突变被定位到,并对双环硝基咪唑 PA-824 也有抗性。机制研究证实 5NP 以 F 依赖性方式被激活,导致 1,10-菲咯啉和 1,10-菲咯啉-5-胺形成主要代谢物。有趣的是,5NP 通过诱导巨噬细胞自噬也能杀死天然耐药的细胞内细菌。构效关系研究表明,硝基对 活性是必需的,一种类似物 3-甲基-6-硝基-1,10-菲咯啉,与 5NP 相比,具有更好的 活性和在小鼠中的疗效。这些发现表明,除了对 有直接作用机制外,5NP 还调节宿主机制以杀死细胞内病原体。

相似文献

1
Dual Mechanism of Action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis.5-硝基-1,10-菲啰啉对结核分枝杆菌的双重作用机制。
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.00969-17. Print 2017 Nov.
2
Bactericidal activity of 2-nitroimidazole against the active replicating stage of Mycobacterium bovis BCG and Mycobacterium tuberculosis with intracellular efficacy in THP-1 macrophages.2-硝基咪唑对牛分枝杆菌卡介苗和结核分枝杆菌活跃复制阶段的杀菌活性以及在THP-1巨噬细胞中的细胞内功效。
Int J Antimicrob Agents. 2008 Jul;32(1):40-5. doi: 10.1016/j.ijantimicag.2008.02.022. Epub 2008 Jun 5.
3
Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis.抗结核药物地拉马尼的耐药机制
Tuberculosis (Edinb). 2018 Jan;108:186-194. doi: 10.1016/j.tube.2017.12.006. Epub 2017 Dec 30.
4
Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.在一系列体外和体内模型中对硝基咪唑并吡喃PA-824抗结核分枝杆菌活性进行临床前测试。
Antimicrob Agents Chemother. 2005 Jun;49(6):2294-301. doi: 10.1128/AAC.49.6.2294-2301.2005.
5
Coenzyme F-Dependent Glucose-6-Phosphate Dehydrogenase-Coupled Polyglutamylation of Coenzyme F in Mycobacteria.分枝杆菌中辅酶 F 依赖的葡萄糖-6-磷酸脱氢酶偶联的辅酶 F 多聚谷氨酸化。
J Bacteriol. 2018 Nov 6;200(23). doi: 10.1128/JB.00375-18. Print 2018 Dec 1.
6
A Novel 6-Benzyl Ether Benzoxaborole Is Active against Mycobacterium tuberculosis .新型 6-苄基醚苯并硼唑对结核分枝杆菌有效。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.01205-17. Print 2017 Sep.
7
Loperamide exerts a direct bactericidal effect against M. tuberculosis, M. bovis, M. terrae and M. smegmatis.洛哌丁胺对结核分枝杆菌、牛分枝杆菌、地分枝杆菌和耻垢分枝杆菌具有直接杀菌作用。
Lett Appl Microbiol. 2021 Mar;72(3):351-356. doi: 10.1111/lam.13432. Epub 2020 Dec 1.
8
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.OPC-67683,一种硝基二氢咪唑并恶唑衍生物,在体外和小鼠体内对结核病有显著疗效。
PLoS Med. 2006 Nov;3(11):e466. doi: 10.1371/journal.pmed.0030466.
9
Nontoxic Metal-Cyclam Complexes, a New Class of Compounds with Potency against Drug-Resistant Mycobacterium tuberculosis.无毒金属-环胺配合物,一类对耐药结核分枝杆菌有效的新型化合物。
J Med Chem. 2016 Jun 23;59(12):5917-21. doi: 10.1021/acs.jmedchem.6b00432. Epub 2016 Jun 7.
10
Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis.吲哚卡巴胺是一种治疗耐多药结核病的临床前候选药物。
Sci Transl Med. 2013 Dec 4;5(214):214ra168. doi: 10.1126/scitranslmed.3007355.

引用本文的文献

1
Synthesis, Characterization, and Anti- Application of Redox-Active Ethyl Carbazate-Derivatized Phenanthroline and Its Silver Complexes.氧化还原活性氨基脲衍生菲咯啉及其银配合物的合成、表征与抗应用
ACS Omega. 2025 Jun 13;10(27):28993-29013. doi: 10.1021/acsomega.5c00871. eCollection 2025 Jul 15.
2
Identification and optimization of pyridine carboxamide-based scaffold as a drug lead for .鉴定并优化吡啶甲酰胺类骨架作为针对. 的药物先导物
Antimicrob Agents Chemother. 2024 Feb 7;68(2):e0076623. doi: 10.1128/aac.00766-23. Epub 2024 Jan 9.
3
Mutations and insights into the molecular mechanisms of resistance of Mycobacterium tuberculosis to first-line.结核分枝杆菌对一线药物耐药的分子机制的突变与见解。
Genet Mol Biol. 2023 Jan 23;46(1 Suppl 2):e20220261. doi: 10.1590/1678-4685-GMB-2022-0261. eCollection 2023.
4
Pharmacokinetic comparability between two populations using nonlinear mixed effect models: a Monte Carlo study.应用非线性混合效应模型比较两种人群的药代动力学:一项蒙特卡罗研究。
J Pharmacokinet Pharmacodyn. 2023 Jun;50(3):189-201. doi: 10.1007/s10928-023-09842-2. Epub 2023 Jan 28.
5
Structural and Functional Characterization of Rv0792c from Mycobacterium tuberculosis: Identifying Small Molecule Inhibitor against HutC Protein.结核分枝杆菌 Rv0792c 的结构与功能分析:鉴定 HutC 蛋白小分子抑制剂。
Microbiol Spectr. 2023 Feb 14;11(1):e0197322. doi: 10.1128/spectrum.01973-22. Epub 2022 Dec 12.
6
NSC19723, a Thiacetazone-Like Benzaldehyde Thiosemicarbazone Improves the Efficacy of TB Drugs and .NSC19723,一种类似噻唑酮的苯甲醛缩氨硫脲,可提高抗结核药物的疗效。
Microbiol Spectr. 2022 Dec 21;10(6):e0259222. doi: 10.1128/spectrum.02592-22. Epub 2022 Oct 31.
7
Identification of small molecules targeting homoserine acetyl transferase from Mycobacterium tuberculosis and Staphylococcus aureus.鉴定结核分枝杆菌和金黄色葡萄球菌同型半胱氨酸乙酰转移酶的小分子靶向药物。
Sci Rep. 2022 Aug 13;12(1):13801. doi: 10.1038/s41598-022-16468-w.
8
The Diverse Biological Activity of Recently Synthesized Nitro Compounds.近期合成的硝基化合物的多样生物活性。
Pharmaceuticals (Basel). 2022 Jun 5;15(6):717. doi: 10.3390/ph15060717.
9
Pharmacophore modeling, docking and the integrated use of a ligand- and structure-based virtual screening approach for novel DNA gyrase inhibitors: synthetic and biological evaluation studies.新型DNA促旋酶抑制剂的药效团建模、对接以及基于配体和结构的虚拟筛选方法的综合应用:合成与生物学评价研究
RSC Adv. 2021 Oct 25;11(55):34462-34478. doi: 10.1039/d1ra05630a.
10
Regulatory Mechanisms of Autophagy-Targeted Antimicrobial Therapeutics Against Mycobacterial Infection.自噬靶向抗分枝杆菌感染抗菌治疗的调控机制。
Front Cell Infect Microbiol. 2021 Mar 22;11:633360. doi: 10.3389/fcimb.2021.633360. eCollection 2021.

本文引用的文献

1
Host-directed therapies for multidrug resistant tuberculosis.针对耐多药结核病的宿主导向疗法。
Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S21-S22. doi: 10.1016/j.ijmyco.2016.09.044. Epub 2016 Nov 14.
2
Learning from the past for TB drug discovery in the future.从过去汲取经验,助力未来结核病药物研发。
Drug Discov Today. 2017 Mar;22(3):534-545. doi: 10.1016/j.drudis.2016.09.025. Epub 2016 Oct 4.
3
New and Old Hot Drug Targets in Tuberculosis.结核病中新的和旧的热门药物靶点
Curr Med Chem. 2016;23(33):3813-3846. doi: 10.2174/1389557516666160831164925.
4
Identification of KasA as the cellular target of an anti-tubercular scaffold.鉴定 KasA 为抗结核支架的细胞靶标。
Nat Commun. 2016 Sep 1;7:12581. doi: 10.1038/ncomms12581.
5
High Beclin-1 Expression in Human Alveolar Macrophage Significantly Correlate with the Bacteriologic Sterilization in Pulmonary Tuberculosis Patients.
Clin Lab. 2016;62(6):1003-7. doi: 10.7754/clin.lab.2015.150833.
6
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.连续三个月每周使用利福喷汀和异烟肼治疗合并感染人类免疫缺陷病毒的结核分枝杆菌感染患者。
AIDS. 2016 Jun 19;30(10):1607-15. doi: 10.1097/QAD.0000000000001098.
7
Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.碳青霉烯类药物治疗多重耐药和广泛耐药结核病:一项系统评价。
Int J Mol Sci. 2016 Mar 12;17(3):373. doi: 10.3390/ijms17030373.
8
Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.贝达喹啉治疗耐多药和广泛耐药结核病。
Eur Respir J. 2016 Feb;47(2):564-74. doi: 10.1183/13993003.00724-2015. Epub 2015 Dec 2.
9
Anti-Pseudomonas aeruginosa activity of 1,10-phenanthroline-based drugs against both planktonic- and biofilm-growing cells.基于1,10-菲咯啉的药物对浮游生长和生物膜生长的铜绿假单胞菌的抗菌活性。
J Antimicrob Chemother. 2016 Jan;71(1):128-34. doi: 10.1093/jac/dkv292. Epub 2015 Sep 27.
10
Linezolid for XDR-TB--Final Study Outcomes.利奈唑胺治疗广泛耐药结核病的最终研究结果。
N Engl J Med. 2015 Jul 16;373(3):290-1. doi: 10.1056/NEJMc1500286.